Naltrexone in the Treatment of Alcohol Dependence

Journal of Addiction Medicine

Volumn 2, Issue 3, 2008, Pages 121-127

  Unterwald, Ellen M ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcoholism; Dopamine; Ethanol; Naltrexone; Opioid peptides; Opioid receptors; Reward circuitry; Treatment

Indexed keywords

EID: 70349197973     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e318182b20f     Document Type: Review

References (99)

1. Altshuler HL, Phillips PE, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980;26:679-688.
2. Myers RD, Borg S, Mossberg R. Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey. Alcohol. 1986;3:383-388.
3. Marfaing-Jallat P, Miceli D, Le Magnen J. Decrease in ethanol consumption by naloxone in naïve and dependent rats. Pharmacol Biochem Behav. 1983;18:537-539.
4. Samson HH, Doyle TF. Oral ethanol self-administration in the rat: effect of naloxone. Pharmacol Biochem Behav. 1985;22:91-99.
5. Froehlich JC, Hars J, Lumeng L, et al. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav. 1990;35:385-390.
6. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881-887.
7. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
8. Chick J, Anton R, Checinski K, et al. A multicenter, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35:587-593.
9. Anton RF, Moak DH, Latham PK, et al. Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol. 2001;21:72-77.
10. Morris PL, Hopwood M, Whelan G, et al. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96:1565-1573.
11. Gastpar M, Bonnet U, Boning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol. 2002;22:592-598.
12. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. New Engl J Med. 2001;345:1734-1739.
13. Johnson BA. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opin Pharmacother. 2006;7:1065-1073.
14. Satoh M, Minami M. Molecular pharmacology of the opioid receptors. Pharmacol Ther. 1995;68:343-364.
15. Mansour A, Fox CA, Akil H, et al. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 1995;18:22-29.
16. Evans CJ. Secrets of the opium poppy revealed. Neuropharmacology. 2004;47(suppl 1):293-299.
17. Belluzzi DJ, Stein L. Enkephalin may mediate euphoria and drive-reduction reward. Nature. 1977;266:556-558.
18. Belluzzi DJ, Stein L. Brain endorphins: possible role in reward and memory formation. Fed Proc. 1979;38:2468-2472.
19. Raynor K, Kong H, Chen Y, et al. Pharmacological characterization of the cloned kappa-, delta- and mu-opioid receptors. Mol Pharmacol. 1994;45:330-334.
20. Goldstein A, Naidu A. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol Pharmacol. 1989;36:265-272.
21. Peng X, Knapp BI, Bidlack JM, et al. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem. 2007;50:2254-2258.
22. Weerts EM, Kin YK, Wand GS, et al. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008;33:653-665.
23. Howlett TA, Rees LH. Endogenous opioid peptides and hypothalamopituitary function. Annu Rev Physiol. 1986;48:527-536
24. Tempel A, Zukin RS, Gardner EL. Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. Life Sci. 1982;31:1401-1404.
25. Unterwald EM, Anton B, To T, et al. Quantitative immuno-localization of mu opioid receptors: regulation by naltrexone. Neuroscience. 1998;85:897-905.
26. Yoburn BC, Kuke MC, Pasternak GW, et al. Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE. Life Sci. 1988;43:1319-1324.
27. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992;13:177-184.
28. Bals-Kubik R, Shippenberg TS, Herz A. Involvement of central mu and delta opioid receptors in mediating the reinforcing effects of β-endorphin in the rat. Eur J Pharmacol. 1990;175:63-69.
29. Mucha RF, Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology. 1985;86:274-280.
30. Bals-Kubik R, Ableitner A, Herz A, et al. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther. 1993;264:489-495.
31. Devine DP, Wise RA. Self-administration of morphine, DAMGO, and DPDPE into the ventral tegmental area of rats. J Neurosci. 1994;14:1978-1984.
32. Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA. 1992;89:2046-2050.
33. Devine DP, Leone P, Pocock D, et al. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J Pharmacol Exp Ther. 1993;266:1236-1246.
34. Self DWL, Nestler EJ. Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci. 1996;18:463-495.
35. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278:52-58.
36. Hollister LE, Johnson K, Boukhabza D, et al. Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend. 1981;8:37-41.
37. Malcolm R, O'Neil PM, Von JM, et al. Naltrexone and dysphoria: a double-blind placebo controlled trial. Biol Psychiatry. 1987;22:710-716.
38. Miotto K, McCann M, Basch J, et al. Naltrexone and dysphoria: fact or myth? Am J Addict. 2002;11:151-160.
39. White DA, Hwang ML, Holtzman SG. Naltrexone-induced conditioned place aversion following a single dose of morphine in the rat. Pharmacol Biochem Behav. 2005;81:451-458.
40. Sakoori K, Murphy NP. Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology. 2004;172:129-136.
41. Vaccarino AL, Plamondon H, Melzack R. Analgesic and aversive effects of naloxone in BALB/C mice. Exp Neurol. 1992;117:216-218.
42. Skoubis PD, Matthew HW, Walwyn WM, et al. Naloxone fails to produced conditioned place aversion in mu-opioid receptor knock-out mice. Neuroscience. 2001;106:757-763.
43. Skoubis PD, Lam HA, Shoblock J, et al. Endogenous enkephalins, not endorphins, modulate basal hedonic state in mice. Eur J Neurosci. 2005;21:1379-1384.
44. Wang D, Raehal KM, Bilsky EJ, et al. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem. 2001;77:1590-1600.
45. Shoblock JR, Maidment NT. Constitutively active mu opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphine-dependent mice. Neuropsychopharmacology. 2006;31:171-177.
46. Easterling KW, Holtzman SG. Discriminative stimulus effects of naltrexone after a single dose of morphine in the rat. J Pharmacol Exp Ther. 1999;288:1269-1277.
47. Schulteis G, Morse AC, Liu J. Repeated experience with naloxone facilitates acute morphine withdrawal: potential role for conditioning processes in acute opioid dependence. Pharmacol Biochem Behav. 2003;76:493-503.
48. Heishman SJ, Stitzer ML, Bigelow GE, et al. Acute opioid physical dependence in humans: effe of naloxone at 6 and 24 ours postmorphine. Pharmacol Biochem Behav. 1990;36:393-399.
49. Koob GF, Roberts AJ, Schulteis G, et al. Neurocircuitry of targets of ethanol reward and dependence. Alcohol Clin Exp Res. 1998;22:3-9.
50. Littleton JM. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med. 2007;1:115-125.
51. Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 2007;30:399-406.
52. Imperato A, Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther. 1986;239:221-229.
53. Rassnick S, Pulvirenti L, Koob GF. Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. Psychopharmacology. 1992;109:92-98.
54. Samsom HH, Hodge CW, Tolliver GA, et al. Effect of dopamine agonists and antagonists on ethanol reinforced behavior: the involvement of the nucleus accumbens. Brain Res Bull. 1993;30:133-141.
55. Lyness WH, Smith FL. Influence of dopaminergic and serotonergic neurons on intravenous ethanol self-administration in the rat. Pharmacol Biochem Behav. 1992;42:187-192.
56. Rassnick S, Stinus L, Koob GF. The effects of 6-hydroxydopamine lesions of the nucleus accumbens and the mesolimbic dopamine system on oral self-administration of ethanol in the rat. Brain Res. 1993;623:16-24.
57. Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry. 1996;53:250-257.
58. Froehlich JC. Genetic factors in alcohol self-administration. J Clin Psychiatry. 1995;56:15-23.
59. Krishnan-Sarin S, Wand GS, Li X-W, et al. Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. Pharmacol Biochem Behav. 1995;52:153-159.
60. King AC, Volpicelli JR, Frazer A, et al. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology. 1997;129:15-22.
61. Volpicelli JR, Watson NT, King AC, et al. Effect of naltrexone on alcohol 'high' in alcoholics. Am J Psychiatry. 1995;152:613-615.
62. Roberts AJ, McDonald JS, Heyser CJ, et al. Mu opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther. 2000;293:1002-1008.
63. Stromberg MF, Casale M, Volpicelli L, et al. A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol comsumption in the rat. Alcohol. 1998;15:281-289.
64. Froehlich JC, Zweifel M, Harts J, et al. Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology. 1991;103:467-472.
65. Ryabinin AE, Criado JR, Henriksen SJ, et al. Differential sensitivity of c-Fos expression in hippocampus and other brain regions to moderate and low doses of alcohol. Mol Psychiatry. 1997;2:32-43.
66. Lyons D, Whitlow CT, Smith HR, et al. Brain imaging. Functional consequences of ethanol in the central nervous system. Recent Dev Alcohol. 1998;14:253-284.
67. Hyytia P, Koob GF. GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats. Eur J Pharmacol. 1995;283:151-159.
68. Roberts AJ, Cole M, Koob GF. Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. Alcohol Clin Exp Res. 1996;20:1289-1298.
69. Moller C, Wiklund L, Sommer W, et al. Decreased experimental anxiety and voluntary ethanol consumption in rats following central but not basolateral amygdala lesions. Brain Res. 1997;760:94-101.
70. Mereu G, Fadda F, Gessa GL. Ethanol stimulates the firing rate of nigral dopaminergic neurons in unanesthetized rats. Brain Res. 1984;292:63-69.
71. Weiss F, Lorang MT, Bloom FE, et al. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther. 1993;267:250-258.
72. Heyser CJ, Roberts AJ, Schulteis G, et al. Central administration of an opiate antagonist decreases oral ethanol self-administration in rats. Alcohol Clin Exp Res. 1999;23:1468-1476.
73. Foster KL, McKay PF, Seyoum R, et al. GABAA and opioid receptors of the central nucleus of the amygdala selectively regulate ethanol-maintained behaviors. Neuropsychopharmacology. 2004;29:269-284.
74. Hyytia P, Kiianmaa K. Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats. Alcohol Clin Exp Res. 2001;25:25-33.
75. Lasek AW, Janak PH, He L, et al. Downregulation of mu opioid receptor by RNA interference in the ventral tegmental area reduces ethanol consumption in mice. Genes Brain Behav. 2007;6:728-735.
76. Olmstead MC, Franklin KB. The development of a conditioned place preference to morphine: effects of microinjections into various CNS sites. Behav Neurosci. 1997;111:1324-1334.
77. Soderman AS, Unterwald EM. Cocaine reward and hyperactivity in the rat: sites of mu opioid receptor modulation. Neuroscience. 2008;154:1506-1516.
78. Alheid GF, Heimer L. New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata. Neuroscience. 1988;27:1-39.
79. Freedman LJ, Cassell MD. Distribution of dopamine fibers in the central division of the extended amygdala of the rat. Brain Res. 1994;633:234-252.
80. Klitenick MA, DeWitte P, Kalivas PW. Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study. J Neurosci. 1992;12:2623-2632.
81. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12:483-489.
82. Chamberlin NL, Mansour A, Watson SJ, et al. Localization of mu-opioid receptors on amygdaloid projection neurons in the parabrachial nucleus of the rat. Brain Res. 1999;827:198-204.
83. Chieng BC, Christie MJ, Osborne PB. Characterization of neurons in the rat central nucleus of the amygdala: cellular physiology, morphology, and opioid sensitivity. J Comp Neurol. 2006;297:910-927
84. Rodaros D, Caruana DA, Amir S, et al. Corticotropin-releasing factor projections from limbic forebrain and paraventricular nucleus of the hypothalamus to the region of the ventral tegmental area. Neuroscience. 2007;150:8-13.
85. Zahm DS, Jensen SL, Williams ES, et al. Direct comparison of projections from the central amygdaloid region and nucleus accumbens shell. Eur J Neurosci. 1999;11:1119-1126.
86. Zhu W, Pan ZZ. Mu-opioid-mediated inhibition of glutamate synaptic transmission in rat central amygdala neurons. Neuroscience. 2005;133:97-103.
87. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335-1341.
88. Jaffe AJ, Rounsaville B, Chang G, et al. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consul Clin Psychol. 1996;64:1044-1053.
89. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546-1552.
90. Ray LA, Hutchinson KE. Effects of naltrexone on alcohol sensitivity and genetics moderators of medication response. Arch Gen Psychiatry. 2007;9:1069-1077.
91. Gelernter J, Gueorguieva R, Kranzler HR, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res. 2007;31:555-563.
92. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA. 1998;95:9608-9613.
93. Wand GS, McCaul M, Yang X, et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology. 2002;26:106-114.
94. Hernandez-Avila C, Wand G, Luo X, et al. association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (ORPM1). Am J Med Genet. 2003;118B:60-65.
95. Smolka M, Sander T, Schmidt L, et al. Mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal. Psychoneuroendocrinology. 1999;24:629-638.
96. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36:544-552.
97. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci. 1998;18:10663-10671.
98. Liu X, Weiss F. Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci. 2002;22:7856-7861.
99. Burattini C, Gill TM, Aicardi G, et al. The ethanol self-administration context as a reinstatement cue: acute effects of naltrexone. Neuroscience. 2006;139:877-887.